Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05077709
Title IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors IO Biotech
Age Groups: senior | adult
Covered Countries USA | ESP

Additional content available in CKB BOOST